Immuneering

Immuneering, based in Cambridge, the United States, is a biotechnology company. Immuneering is a biotechnology company developing oncology treatments based on 'Deep Cyclic Inhibitors', a pulsed dosing approach to MAPK-pathway inhibition intended to reduce cancer resistance while improving tolerability. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing Atebimetinib in pancreatic ductal adenocarcinoma, melanoma and non-small-cell lung cancer. The largest, NCT07562152 (Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma), plans to enrol 510 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.